# Prophylactic Regimen With Intrathecal Thiotepa in SVZ-positive or Meningeal-risk Glioblastoma

> **NCT07511725** · PHASE2 · RECRUITING · sponsor: **Second Affiliated Hospital, School of Medicine, Zhejiang University** · enrollment: 38 (estimated)

## Conditions studied

- Glioblastoma (GBM)

## Interventions

- **PROCEDURE:** Maximal surgical resection
- **RADIATION:** Concomitant Chemoradiotherapy (Stupp backbone)
- **DRUG:** Preventive Intrathecal Thiotepa

## Key facts

- **NCT ID:** NCT07511725
- **Lead sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-04
- **Primary completion:** 2028-01-04
- **Final completion:** 2029-01-04
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2026-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07511725

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07511725, "Prophylactic Regimen With Intrathecal Thiotepa in SVZ-positive or Meningeal-risk Glioblastoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07511725. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*